<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Drug Investig</journal-id><journal-id journal-id-type="iso-abbrev">Clin Drug Investig</journal-id><journal-title-group><journal-title>Clinical Drug Investigation</journal-title></journal-title-group><issn pub-type="ppub">1173-2563</issn><issn pub-type="epub">1179-1918</issn><publisher><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">4079386</article-id><article-id pub-id-type="publisher-id">165</article-id><article-id pub-id-type="doi">10.1007/s40261-013-0165-y</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sharma</surname><given-names>Amit</given-names></name><address><email>sharmaaxs@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Marshall</surname><given-names>Thomas S.</given-names></name><address><email>t.marshall@abbvie.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Khan</surname><given-names>Samina S.</given-names></name><address><email>samina.khan@abbvie.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Johns</surname><given-names>Beverly</given-names></name><address><email>beverly.a.johns@abbvie.com</email></address><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Nephrian Inc., 870 Paseo Santa Cruz, Thousand Oaks, CA 91320-6779 USA </aff><aff id="Aff2"><label/>AbbVie, Inc., 1 North Waukegan Road, North Chicago, IL 60064 USA </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>1</month><year>2014</year></pub-date><pub-date pub-type="ppub"><year>2014</year></pub-date><volume>34</volume><issue>2</issue><fpage>163</fpage><lpage>163</lpage><permissions><copyright-statement>&#x000a9; Springer International Publishing Switzerland 2013</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d30e85" ext-link-type="doi" xlink:href="10.1007/s40261-013-0151-4"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer International Publishing Switzerland 2014</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Clin Drug Investig DOI 10.1007/s40261-013-0151-4</title><p>A Published-Ahead-of-Print version of this article was made available online at <ext-link ext-link-type="uri" xlink:href="http://link.springer.com/article/10.1007/s40261-013-0151-4">http://link.springer.com/article/10.1007/s40261-013-0151-4</ext-link> on 09 November 2013. Errors were subsequently identified in that version of the article, and the following corrections should be noted:</p><p><bold>Section&#x000a0;3.1, line 5</bold>, which previously read:</p><p>&#x0201c;As shown in Table&#x000a0;2, among US patients, 29 (56.9&#x000a0;%) in the paricalcitol group and 16 (34.0&#x000a0;%) in the cinacalcet group reached this endpoint (a difference of 23&#x000a0;%, <italic>p</italic>&#x000a0;=&#x000a0;0.0235).&#x0201d;</p><p>Should read:</p><p>&#x0201c;As shown in Table&#x000a0;3, among US patients, 29 (56.9&#x000a0;%) in the paricalcitol group and 16 (34.0&#x000a0;%) in the cinacalcet group reached this endpoint (a difference of 23&#x000a0;%, <italic>p</italic>&#x000a0;=&#x000a0;0.0235).&#x0201d;</p><p><bold>Section&#x000a0;3.3, first paragraph, line 8</bold>, which previously read:</p><p>&#x0201c;Table&#x000a0;3 also shows the difference between the paricalcitol and cinacalcet groups in the proportions of patients who responded, based on each endpoint included (based on data in Table&#x000a0;2).&#x0201d;</p><p>Should read:</p><p>&#x0201c;Table&#x000a0;4 also shows the difference between the paricalcitol and cinacalcet groups in the proportions of patients who responded, based on each endpoint included (based on data in Table&#x000a0;3).&#x0201d;</p><p><bold>Section&#x000a0;3.3, third paragraph, line 1</bold>, which previously read:</p><p>&#x0201c;Figure&#x000a0;1 is a scatterplot of all 1,000 bootstrap replicates, with the <italic>x</italic>-axis representing the incremental cost and the <italic>y</italic>-axis representing the incremental effectiveness of the paricalcitol-based regimen compared with the cinacalcet-based regimen, where effectiveness is the proportion of subjects reaching an iPTH level of 150&#x02013;300&#x000a0;pg/mL.&#x0201d;</p><p>Should read:</p><p>&#x0201c;Figure&#x000a0;1 is a scatterplot of all 1,000 bootstrap replicates, with the <italic>x</italic>-axis representing the incremental effectiveness and the <italic>y</italic>-axis representing the incremental cost of the paricalcitol-based regimen compared with the cinacalcet-based regimen, where effectiveness is the proportion of subjects reaching an iPTH level of 150&#x02013;300&#x000a0;pg/mL.&#x0201d;</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s40261-013-0151-4.</p></fn></fn-group></back></article>